Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare

Cipher Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products either directly in Canada or indirectly through partners in Canada, the United States and South America. Its Dermatology products include Actikerall, Epuris, Ozanex and Vaniqa. Its Hospital Acute Care products include Aggrastat and Brinavess. Its Out-Licensed products include Absorica, ConZip and Lipofen. The Company is also focused on building a portfolio of prescription medicines that serve unmet medical needs. The Company's product pipeline development programs including MOB-015, DTR-001, and CF-101. The Company's subsidiaries include Cipher US Holdings Inc., Cipher US Holdco LLC, and Cipher Pharmaceuticals US LLC.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc > CPH: Debt-Free since October 30, 2020

<< Previous

Bullboard Posts

Next >>

Post by stockfyon Jan 20, 2021 5:33pm

219 Views

Post# 32340417

CPH: Debt-Free since October 30, 2020

CPH has been debt free since October 30, 2020, facts below:

"The Company generated $5.5 million in cash from operating activities during the nine-month period ended September 30, 2020 . As of September 30, 2020 , the Company had cash of $4.7 million and $1.7 million drawn on the credit facility. The Company's credit facility has been paid off as at October 30, 2020 ."

<< Previous

Bullboard Posts

Next >>

Morning Market Outlook for May 22, 2024